Experimental cancer pill tested in advanced tumors – trial halted early
NCT ID NCT04892017
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 42 times
Summary
This early-stage trial tested a new drug called DCC-3116 (inlexisertib) in 91 people with advanced or metastatic solid tumors that have RAS/MAPK pathway mutations. The drug was given alone or combined with other targeted therapies. The study aimed to find safe doses and check for side effects, but it was terminated early. It is unclear if the drug will move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NEXT Oncology
Austin, Texas, 78758, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Wisconsin Clinical Science Center
Madison, Wisconsin, 53792, United States
-
Washington University Siteman Cancer Center
St Louis, Missouri, 63108, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DCC-3116 (inlexisertib) taken as a pill, alone or with other targeted drugs (trametinib, binimetinib, or sotorasib)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors that have specific genetic mutations.
What could go wrong
This was a very early (phase 1/2) trial that was terminated, meaning it stopped early. It involved only 91 participants, so results may not apply widely, and side effects are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.